Weiss Ratings Reiterates Sell (D-) Rating for Oruka Therapeutics (NASDAQ:ORKA)

Key Points

• Weiss Ratings has issued a sell (D-) rating for Oruka Therapeutics (NASDAQ: ORKA), reiterating concerns about the company's stock performance.
• In contrast, other analysts like BTIG Research and HC Wainwright have given buy ratings with target prices of $56.00 and $45.00 respectively, indicating mixed sentiment about the stock.
• Oruka Therapeutics' stock recently opened at $22.61, with a 52-week range between $5.49 and $31.13, reflecting significant volatility over the past year.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Other research analysts have also issued research reports about the company. BTIG Research restated a "buy" rating and set a $56.00 target price on shares of Oruka Therapeutics in a research report on Monday, September 29th. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. HC Wainwright reiterated a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Monday, August 18th. Finally, Wedbush reiterated an "outperform" rating and issued a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $42.00.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $22.61 on Wednesday. Oruka Therapeutics has a 52-week low of $5.49 and a 52-week high of $31.13. The firm has a market capitalization of $846.74 million, a PE ratio of -8.05 and a beta of -0.29. The stock has a fifty day simple moving average of $15.85 and a two-hundred day simple moving average of $12.83.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02. On average, sell-side analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its position in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock valued at $31,000 after acquiring an additional 2,306 shares during the period. Bank of America Corp DE increased its position in shares of Oruka Therapeutics by 287.6% in the 2nd quarter. Bank of America Corp DE now owns 18,849 shares of the company's stock valued at $211,000 after acquiring an additional 13,986 shares during the period. Cable Car Capital LP increased its position in shares of Oruka Therapeutics by 33.3% in the 2nd quarter. Cable Car Capital LP now owns 600,000 shares of the company's stock valued at $6,726,000 after acquiring an additional 150,000 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at $167,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Oruka Therapeutics by 22.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the company's stock valued at $591,000 after acquiring an additional 9,828 shares during the period. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.